NASDAQ:PRTK Paratek Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Paratek Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.26 +0.13 (+6.10%) (As of 07/7/2022 11:46 AM ET) Add Compare Share Today's Range$2.12▼$2.2950-Day Range$1.73▼$2.5152-Week Range$1.60▼$6.91Volume21,320 shsAverage Volume968,007 shsMarket Capitalization$123.12 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Paratek Pharmaceuticals MarketRank™ ForecastAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside820.1% Upside$20.33 Price TargetShort InterestHealthy20.17% of Float Sold ShortDividend StrengthN/ASustainability-2.98Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to $0.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.56 out of 5 starsMedical Sector615th out of 1,433 stocksPharmaceutical Preparations Industry300th out of 683 stocks 3.8 Analyst's Opinion Consensus RatingParatek Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.33, Paratek Pharmaceuticals has a forecasted upside of 820.1% from its current price of $2.21.Amount of Analyst CoverageParatek Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted20.17% of the float of Paratek Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverParatek Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Paratek Pharmaceuticals has recently decreased by 7.18%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldParatek Pharmaceuticals does not currently pay a dividend.Dividend GrowthParatek Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreParatek Pharmaceuticals has received a -34.94% net impact score from Upright. The largest negative impact of Paratek Pharmaceuticals in category "Physical diseases" is driven by its "Tetracyclines" product. See details.Environmental SustainabilityThe Environmental Impact score for Paratek Pharmaceuticals is -2.98. Previous Next 1.1 News and Social Media Coverage News SentimentParatek Pharmaceuticals has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.Search InterestOnly 2 people have searched for PRTK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Paratek Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.Percentage Held by Institutions59.46% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Paratek Pharmaceuticals are expected to grow in the coming year, from ($0.71) to $0.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Paratek Pharmaceuticals is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Paratek Pharmaceuticals is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Paratek Pharmaceuticals (NASDAQ:PRTK) StockParatek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.Read More PRTK Stock News HeadlinesJune 21, 2022 | seekingalpha.comParatek Pharmaceuticals stock soars postmarket on fast track designation for NuzyraJune 21, 2022 | finance.yahoo.comParatek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)June 8, 2022 | finance.yahoo.comEven after rising 25% this past week, Paratek Pharmaceuticals (NASDAQ:PRTK) shareholders are still down 89% over the past five yearsMay 16, 2022 | finance.yahoo.comParatek Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceMay 5, 2022 | finance.yahoo.comParatek Pharmaceuticals (PRTK) Q1 2022 Earnings Call TranscriptMay 5, 2022 | seekingalpha.comParatek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2022 Results - Earnings Call TranscriptMay 4, 2022 | seekingalpha.comParatek Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationMay 4, 2022 | seekingalpha.comParatek Pharmaceuticals Q1 2022 Earnings PreviewMay 4, 2022 | seekingalpha.comParatek Pharmaceuticals GAAP EPS of -$0.35 in-line, revenue of $24.86M misses by $2.29MMay 4, 2022 | finance.yahoo.comParatek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 MillionMay 3, 2022 | benzinga.comEarnings Outlook For Paratek PharmaceuticalsApril 26, 2022 | finance.yahoo.comParatek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022April 9, 2022 | finance.yahoo.comParatek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Profit OutlookMarch 16, 2022 | benzinga.comLooking Into Paratek Pharmaceuticals's Return On Capital EmployedMarch 14, 2022 | seekingalpha.comParatek Pharmaceuticals GAAP EPS of -$1.22 misses by $0.31, revenue of $130.16M misses by $3.57MMarch 14, 2022 | apnews.comParatek: Q4 Earnings SnapshotMarch 14, 2022 | finance.yahoo.comParatek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 MillionMarch 12, 2022 | benzinga.comParatek Pharmaceuticals's Earnings: A PreviewMarch 8, 2022 | finance.yahoo.comParatek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA® (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium complexMarch 2, 2022 | finance.yahoo.comParatek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022February 10, 2022 | benzinga.comWBB Securities Upgrades Paratek Pharmaceuticals to Strong Buy, Announces $11 Price TargetFebruary 3, 2022 | finance.yahoo.comKalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ...December 16, 2021 | finance.yahoo.comChina's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin InfectionsDecember 16, 2021 | finance.yahoo.comChina's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin InfectionsDecember 10, 2021 | finance.yahoo.comInvestors in Paratek Pharmaceuticals (NASDAQ:PRTK) from five years ago are still down 67%, even after 11% gain this past weekSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PRTK Previous SymbolNASDAQ:TSPT CUSIP89354M10 CIK1178711 Webwww.paratekpharma.com Phone(617) 807-6600Fax617-275-0039Employees207Year Founded1996Company Calendar Last Earnings5/04/2022Today7/07/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$20.33 High Stock Price Forecast$30.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+585.8%Consensus RatingStrong Buy Rating Score (0-4)3.5 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,080,000.00 Net Margins-42.31% Pretax Margin-41.88% Return on EquityN/A Return on Assets-32.77% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.18 Sales & Book Value Annual Sales$130.16 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value($2.62) per share Price / Book-0.86Miscellaneous Outstanding Shares54,480,000Free Float50,121,000Market Cap$123.12 million OptionableOptionable Beta1.46 Social Links Paratek Pharmaceuticals Frequently Asked Questions Should I buy or sell Paratek Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" Paratek Pharmaceuticals stock. View analyst ratings for Paratek Pharmaceuticals or view top-rated stocks. What is Paratek Pharmaceuticals' stock price forecast for 2022? 2 brokerages have issued 12 month price objectives for Paratek Pharmaceuticals' stock. Their PRTK stock forecasts range from $11.00 to $30.00. On average, they predict Paratek Pharmaceuticals' share price to reach $20.33 in the next year. This suggests a possible upside of 799.7% from the stock's current price. View analysts' price targets for Paratek Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Paratek Pharmaceuticals' stock performed in 2022? Paratek Pharmaceuticals' stock was trading at $4.49 at the beginning of the year. Since then, PRTK shares have decreased by 49.7% and is now trading at $2.26. View the best growth stocks for 2022 here. When is Paratek Pharmaceuticals' next earnings date? Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Paratek Pharmaceuticals. How were Paratek Pharmaceuticals' earnings last quarter? Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its quarterly earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, hitting the consensus estimate of ($0.35). The specialty pharmaceutical company had revenue of $24.86 million for the quarter, compared to the consensus estimate of $27.15 million. During the same quarter in the previous year, the company earned ($0.39) earnings per share. View Paratek Pharmaceuticals' earnings history. What guidance has Paratek Pharmaceuticals issued on next quarter's earnings? Paratek Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155.00 million-$170.00 million, compared to the consensus revenue estimate of $166.11 million. Who are Paratek Pharmaceuticals' key executives? Paratek Pharmaceuticals' management team includes the following people: Mr. Michael F. Bigham CPA, CPA, M.B.A., MBA, Exec. Chairman (Age 64, Pay $934.7k)Dr. Evan Loh FACC, FAHA, M.D., CEO & Director (Age 63, Pay $1.07M)Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 55, Pay $735.48k) (LinkedIn Profile)Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 47)Mr. Jason Burdette, Sr. VP of Technical OperationsMr. Ben Strain, VP of Investor Relations & Corp. Communications and Chief of Staff to the CEOMr. William M. Haskel, Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 60) (LinkedIn Profile)Ms. Karen McGrath, Sr. VP of HRMr. Randall B. Brenner, Chief Devel. & Regulatory Officer (Age 49) (LinkedIn Profile) Who are some of Paratek Pharmaceuticals' key competitors? Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN) and Nektar Therapeutics (NKTR). View all of PRTK's competitors. What other stocks do shareholders of Paratek Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL). What is Paratek Pharmaceuticals' stock symbol? Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK." How do I buy shares of Paratek Pharmaceuticals? Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Paratek Pharmaceuticals' stock price today? One share of PRTK stock can currently be purchased for approximately $2.26. How much money does Paratek Pharmaceuticals make? Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $123.12 million and generates $130.16 million in revenue each year. The specialty pharmaceutical company earns $-59,080,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. How many employees does Paratek Pharmaceuticals have? Paratek Pharmaceuticals employs 207 workers across the globe. When was Paratek Pharmaceuticals founded? Paratek Pharmaceuticals was founded in 1996. How can I contact Paratek Pharmaceuticals? Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for Paratek Pharmaceuticals is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039. This page (NASDAQ:PRTK) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
